Advances in therapy for pediatric sarcomas

Aaron Weiss, Jonathan Gill, John Goldberg, Joanne Lagmay, Holly Spraker-Perlman, Rajkumar Venkatramani, Damon Reed

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy.

Original languageEnglish (US)
Article number395
JournalCurrent oncology reports
Issue number8
StatePublished - Aug 2014


  • Oncology
  • Pediatric sarcomas
  • Rare malignancies
  • Sarcomas
  • Therapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Advances in therapy for pediatric sarcomas'. Together they form a unique fingerprint.

Cite this